Amicus Therapeutics Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on delivering life-changing therapies, Amicus strives to improve the lives of individuals with rare and devastating diseases. The company is committed to advancing science, developing transformative medicines, and ensuring access to those therapies for patients in need. Amicus fosters a collaborative and compassionate approach, working closely with patient advocacy groups, healthcare professionals, and regulatory authorities to make a meaningful impact in the lives of the communities it serves.

Amicus Therapeutics Inc is primarily present in the United States.

Amicus Therapeutics Inc has achieved significant milestones in its journey. Some notable accomplishments include the approval of Galafold, a breakthrough therapy for Fabry disease, by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company has made remarkable progress in developing innovative therapies for rare genetic diseases such as Pompe disease and other lysosomal storage disorders. Amicus Therapeutics Inc has successfully conducted clinical trials and obtained positive results, showcasing their commitment to advancing medical science and improving patients' lives. Their unwavering dedication has positioned them as a leading player in the biopharmaceutical industry.

Amicus Therapeutics Inc is a biopharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2002, Amicus Therapeutics focuses on developing advanced therapies for rare and orphan diseases. The company's innovative approach is based on the principles of personalized medicine, utilizing breakthrough science and technology. Over the years, Amicus Therapeutics has established itself as a leader in the field, with a strong dedication to improving the lives of patients with devastating genetic diseases. Through its robust research and development efforts, Amicus Therapeutics has successfully advanced several potential treatments, striving to bring hope and transformative therapies to those in need.

The main competitors of Amicus Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Sanofi Genzyme.

Amicus Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Amicus Therapeutics Inc. revolves around developing advanced therapies for rare and orphan diseases. The company focuses on utilizing its Chaperone-Advanced Replacement Therapy (CHART™) platform to deliver enzyme replacement therapies (ERTs) for individuals suffering from lysosomal storage disorders (LSDs). As a biopharmaceutical company, Amicus Therapeutics aims to address unmet medical needs through innovative drug research and development. By leveraging their expertise in protein misfolding and folding, Amicus Therapeutics aims to improve the lives of patients with genetic diseases.

Amicus Therapeutics KGV ir -61,18.

Amicus Therapeutics KUV ir 6,58.

AlleAktien kvalitātes vērtējums Amicus Therapeutics ir 4/10.

gaidāmā Amicus Therapeutics apgrozījums ir 527,36 milj. USD.

gaidāmā Amicus Therapeutics peļņa ir -56,73 milj. USD.

Amicus Therapeutics Inc (Nasdaq: FOLD) aims to develop and manufacture novel therapies for people with rare and severe diseases. The biotechnology company, based in Cranbury, New Jersey, USA, focuses on researching and developing drugs that aim to influence the natural metabolism of proteins in the body to treat diseases caused by mutations in genes. The business model of Amicus Therapeutics is based on the discovery and development of therapies specialized in treating rare and severe diseases. The company works closely with patients and their families to gain a better understanding of the needs and challenges of these patient groups. Amicus utilizes a proprietary technology platform called Chaperon-Advanced Replacement Therapy (CHART), which allows for the treatment of Ectopic Glycosylation Disorders (EGS) by replacing faulty proteins produced by gene mutations with functional and stable therapeutics. Amicus Therapeutics specializes in the following three areas: 1. Fabry disease: A rare lysosomal metabolic disorder where the Alpha-Galactosidase-A enzyme is not produced normally due to mutations in the GLA gene. Amicus has developed Galafold, the first oral medication for treating Fabry disease, which aims to stabilize the faulty protein. 2. Pompe disease: A lysosomal storage disease characterized by a deficiency of enzymes that help in breaking down glycogen. This results in an accumulation of glycogen in various tissues and organs. Amicus has developed ATB200/AT2221, a combined therapy of enzyme replacement therapy and chaperone therapy aimed at correcting the enzyme deficiency caused by mutation. 3. Phenylketonuria (PKU): A metabolic disorder where an individual lacks the ability to metabolize phenylalanine. This leads to an accumulation of phenylalanine in the body, which can cause impairments to the central nervous system. Amicus has a pipeline of therapeutics in development for treating PKU, including a chaperone platform and an enzyme replacement therapy. Amicus Therapeutics collaborates closely with medical centers, patient organizations, and research institutions to develop innovative therapies for rare and severe diseases. The company is committed to enhancing the effectiveness and safety of medications, helping to improve the quality of life for affected individuals. By focusing on rare and severe diseases, Amicus Therapeutics can serve a niche and position itself as an innovator in the biotechnology industry. Overall, Amicus Therapeutics' business model has the potential to achieve significant medical advancements while also being profitable. The company is well-positioned to continue developing innovative therapies for rare and severe diseases that can improve the lives of patients and their families.

Amicus Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Amicus Therapeutics vai uzņēmums nedod dividendes.

Amicus Therapeutics ISIN ir US03152W1099.

Amicus Therapeutics WKN ir A0MSMZ.

Amicus Therapeutics simbols ir FOLD.

Pēdējo 12 mēnešu laikā Amicus Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Amicus Therapeutics plāno maksāt dividendes 0 USD apmērā.

Amicus Therapeutics pašreizējā dividendu rentabilitāte ir .

Amicus Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Amicus Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Amicus Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Amicus Therapeutics apmērā 0 USD, kas tika izmaksāta 26.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.08.2024..

Pēdējās dividendes izmaksa notika 26.08.2024..

Gadā 2023, Amicus Therapeutics izmaksāja 0 USD dividendes.

Amicus Therapeutics dividendes tiek izmaksātas USD.